NASDAQ:HPTX »

• 
  Company News » Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc. Stockholders

  Business Wire - September 10, 2014, 22:57 GMT

  Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data. On September 8, 2014, the Company announced that it is terminating development of DiaPep277 for

  Read full story »
• 
  Company News » EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Hyperion Therapeutics, Inc. — HPTX

  Business Wire - September 8, 2014, 17:39 GMT

  The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Hyperion Therapeutics, Inc. (NASDAQ:HPTX) resulting from allegations that the Company may have issued materially false statements to investors. On September 8, 2014, Hyperion Therapeutics shocked the market when it announced that it would terminate the development of its diabetes drug, DiaPep277,

  Read full story »